Godavari Drugs Intrinsic Value
Godavari Drugs intrinsic value. Godavari Drugs (GODAVARI) median intrinsic value is ₹94.30 from 9 valuation models (range ₹35–₹222), vs current price ₹117.00 — -19.4% downside (Trading Above Median Value), margin of safety -24.1%. Read Godavari Drugs dividend policy for the complete payout history and dividend yield track record.
GODAVARI Valuation Methods Summary — DCF, Graham Number & P/E
Godavari Drugs intrinsic value across 9 models vs current price ₹117.00 — upside/downside and value range per method. Compare with GODAVARI stock valuation models to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹114.40 | ₹91.52 - ₹137.28 | -2.2% | EPS: ₹5.20, Sector P/E: 22x |
| Book Value Method | asset | ₹152.00 | ₹136.80 - ₹167.20 | +29.9% | Book Value/Share: ₹76.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹222.00 | ₹199.80 - ₹244.20 | +89.7% | Revenue/Share: ₹111.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹110.00 | ₹99.00 - ₹121.00 | -6.0% | EBITDA: ₹11.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹46.80 | ₹37.44 - ₹56.16 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹35.10 | ₹31.59 - ₹38.61 | -70.0% | EPS Growth: 0.8%, Fair P/E: 0.7x |
| Growth Adjusted P/E | growth | ₹74.59 | ₹67.13 - ₹82.05 | -36.2% | Revenue Growth: -8.7%, Adj P/E: 14.3x |
| ROE Based Valuation | profitability | ₹58.50 | ₹52.65 - ₹64.35 | -50.0% | ROE: 5.3%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹94.30 | ₹84.87 - ₹103.73 | -19.4% | EPS: ₹5.20, BVPS: ₹76.00 |
GODAVARI Intrinsic Value vs Market Price — All Valuation Models
Godavari Drugs fair value range ₹35–₹222 vs current market price ₹117.00 across 9 valuation models. For current market price and key ratios, visit GODAVARI stock price BSE.
GODAVARI Intrinsic Value Analysis — Undervalued or Overvalued?
Godavari Drugs median intrinsic value ₹94.30, current price ₹117.00 — Trading Above Median Value by 19.4%, margin of safety -24.1%.
What is the intrinsic value of GODAVARI?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Godavari Drugs (GODAVARI) is ₹94.30 (median value). With the current market price of ₹117.00, this represents a -19.4% variance from our estimated fair value.
The valuation range spans from ₹35.10 to ₹222.00, indicating ₹35.10 - ₹222.00.
Is GODAVARI undervalued or overvalued?
Based on our multi-method analysis, Godavari Drugs (GODAVARI) appears to be trading above median value by approximately 19.4%.
GODAVARI Financial Health — Key Ratios vs Industry Benchmarks
Godavari Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.80 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 9.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.56x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GODAVARI Cash Flow Quality — Operating & Free Cash Flow
Godavari Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹1 Cr | ₹-12 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹11 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹18 Cr | ₹12 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹13 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹11 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |